{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-021889","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.502268+00:00","generated_at":"2026-06-24T01:26:59.368435+00:00","sec_items":["2.02","2.05","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Oncocyte Q2 net loss $8.3M; plans RIF to cut $4.5M annual costs","bullets":["Net loss $8.3M ($0.07 EPS) vs $10.5M ($0.12 EPS) YoY; revenue $2.1M, flat.","Reduction in force to cut annual cash comp costs by >$4.5M; severance ~$2.0M in Q3 2022.","Closed underwritten offering of $32.8M and preferred stock offering of $4.9M in net proceeds.","Cash $47.1M as of June 30; annualized op expense reduction of ~$12M expected in 2023.","Appointed Gisela Paulsen President & COO and Anish John CFO, effective Aug 8, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-021889","json":"https://secwatch.observer/filing/0001493152-22-021889.json","markdown":"https://secwatch.observer/filing/0001493152-22-021889.md","text":"https://secwatch.observer/filing/0001493152-22-021889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/0001493152-22-021889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:26:59.368435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"019d9db672","claim":"Anish John was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/0001493152-22-021889-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"19e7c9b0c6","claim":"Gisela Paulsen was appointed as President and Chief Operating Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/0001493152-22-021889-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}